July 2016 Blog Posts (6)

Distinguished Cancer Researcher Alfred G. Knudson, Jr. Dies at 93

Alfred G. Knudson, Jr., MD, PhD (photo), a pioneering cancer researcher who is internationally recognized for his groundbreaking “two-hit” hypothesis, which helped provide the basis for our current understanding of the genetic origins of cancer passed away on July 10, 2016 at 93 years of age.

“The [...] cancer research world as a whole has lost a true visionary with the passing of Knudson. He proposed the two-hit hypothesis many years before the molecular technologies needed…

Continue

Added by Editorial Team on July 12, 2016 at 10:00am — No Comments

European Commission Extends Conditional Market Authorization for Brentuximab Vedotin

Following a positive opinion from the Committee for Medicinal Products for Human Use issued on May 26, 2016, the European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology). The drug is now…

Continue

Added by Editorial Team on July 11, 2016 at 11:30am — No Comments

Men's Health: Focus on Prostate Screening

Contributing Editor: Jon Elion, MD, FACC, Founder/President of ChartWise Medical Systems.

As a cardiologist, it is tempting for me to use this platform to talk about heart disease. Instead I have decided to push myself beyond that, connecting to my cardiology…

Continue

Added by Editorial Team on July 6, 2016 at 9:30pm — No Comments

Clinical trial of Novel Immune-based Therapy may Benefit Patients with Advanced Pancreatic Tumors

While immune therapy has proven effective in treating certain types of cancer, especially lung cancer and melanoma, tumors of the pancreas remain among the most difficult to treat and, so far, are impervious to immune-based therapies.

Now, for the first time, a new study in mice has shown that immunotherapy against pancreatic cancer can be effective when given in conjunction with drugs that break up the fibrous tissue in these tumors.

The study, from Washington University…

Continue

Added by Editorial Team on July 4, 2016 at 11:00am — No Comments

Phase III Trial Finds that Anti-interleukin-1 alpha antibody MABp1 Improves Outcomes Significantly over Placebo

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology’s 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [1]

Xilonix™ (XBiotech) is the first…

Continue

Added by Editorial Team on July 2, 2016 at 11:00am — No Comments

Understanding the impact of Growing Population of Aging Cancer Survivors Critical to Develop Quality Care for this Population

Improved cancer detection and treatment efforts, combined with demographic trends, are creating larger numbers of older cancer survivors who are likely to have other health conditions that impact care and well-being. This is the conclusion of new research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American…

Continue

Added by Editorial Team on July 1, 2016 at 5:00pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+